Bill > S1425

This bill, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act), aims to enable the Federal Trade Commission (FTC) to deter the filing of sham citizen petitions that attempt to interfere with the approval of competing generic drugs or biosimilars. The bill defines a "sham" petition as one that is objectively baseless and intended to interfere with a competitor's business, rather than raise legitimate public health concerns. The FTC can now bring civil actions against individuals or entities that submit or cause the submission of such sham petitions, with the potential for significant civil penalties based on the revenues earned from the affected drug products or a per-day fine for each sham petition. This legislation is intended to foster competition and facilitate the efficient review of legitimate petitions filed in good faith.